Pregnancy Cholestasis Genetics Study Maps Bile Acid Risk

What Is Intrahepatic Cholestasis of Pregnancy?

Intrahepatic cholestasis of pregnancy, often called ICP, is characterized by pruritus, abnormal liver enzymes, and increased serum bile acids. It most often appears in the second or third trimester and typically improves after delivery, but it matters clinically because higher bile acid levels are linked with fetal complications, including preterm birth, meconium-stained amniotic fluid, and stillbirth.

The new Nature Communications study reports that ICP affects about 0.2-2% of pregnancies and analyzed 4,738 women with prior ICP alongside 436,834 female controls. By combining genome-wide association data from major biobanks, researchers identified 26 genome-wide significant associations, including 10 reported as novel, pointing toward biological pathways that regulate bile acid synthesis, LDL cholesterol, and lipid metabolism.

How Could Genetics Improve Pregnancy Cholestasis Care?

The study does not mean that a single gene test can diagnose ICP today. Instead, it adds a more detailed biological map of why some pregnant people may be more vulnerable to bile acid buildup when pregnancy hormones place extra stress on liver transport and metabolism systems. The authors also reported genetic links with pancreatitis, suggesting that ICP may share pathways with other hepatobiliary and metabolic conditions.

For patients, the practical message remains unchanged: new itching in pregnancy, especially on the palms or soles and without a clear rash, should prompt medical evaluation. The Society for Maternal-Fetal Medicine recommends measuring serum bile acids and liver transaminases when ICP is suspected, and current delivery planning is guided mainly by bile acid levels, gestational age, symptoms, and the broader clinical picture.

Why Do Bile Acid Levels Matter for Fetal Risk?

A major Lancet individual patient data meta-analysis found that, in singleton pregnancies affected by ICP, total bile acids of 100 micromol/L or more were associated with a significantly higher stillbirth risk. This threshold is reflected in specialist guidance: SMFM recommends offering delivery at 36 0/7 weeks for patients with total bile acids at or above 100 micromol/L, while those below that threshold are generally managed within a later 36-39 week delivery window depending on circumstances.

Treatment is aimed at reducing maternal symptoms and managing fetal risk rather than curing the genetic or metabolic susceptibility itself. Ursodeoxycholic acid is recommended by SMFM as first-line therapy for maternal symptoms, although randomized trial evidence has shown mixed effects on perinatal outcomes. The new genetics work may help future research target upstream mechanisms, but clinical management should remain individualized and supervised by obstetric and maternal-fetal medicine teams.